Advanced search
Publication Cover
HIV Clinical Trials Volume 15, 2014 - Issue 6
Submit an article Journal homepage
193
Views
12
CrossRef citations to date
0
Altmetric
Original Articles

Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment

Cheryl K. McDonaldTarrant County Infectious Disease Fort Worth, TexasCorrespondence[email protected]
,
Claudia MartorellThe Research InstituteSpringfield, Massachusetts
,
Moti RamgopalMidway Immunology and Research CenterFort Pierce, Florida
,
Francois LaplanteClinique Medicale du Quartier LatinMontreal, Canada
,
Martin FisherBrighton and Sussex Medical SchoolBrighton, UK
,
Frank A. PostKings College HospitalLondon, UK
,
Yapei LiuGilead SciencesFoster City, California
,
Joanne CurleyGilead SciencesFoster City, California
,
Michael E. AbramGilead SciencesFoster City, California
,
Joseph CustodioGilead SciencesFoster City, California
,
Hiba GrahamGilead SciencesFoster City, California
,
Martin S. RheeGilead SciencesFoster City, California
&
Javier SzwarcbergGilead SciencesFoster City, California
 show all
Pages 269-273 | Published online: 22 Dec 2014

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Francisco Antunes. (2017) Atazanavir sulfate + cobicistat for the treatment of HIV infection. Expert Review of Anti-infective Therapy 15:6, pages 569-576.
Read now
Rustin D Crutchley, Rakesh C Guduru & Amy M Cheng. (2016) Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. HIV/AIDS - Research and Palliative Care 8, pages 47-65.
Read now
Jordi Navarro & Adrian Curran. (2016) Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS. HIV/AIDS - Research and Palliative Care 8, pages 175-182.
Read now
Maria Vittoria Cossu, Noemi Astuti, Amedeo Capetti & Giuliano Rizzardini. (2015) Impact and differential clinical utility of cobicistat-boosted darunavir in HIV/AIDS. Virus Adaptation and Treatment 7, pages 47-56.
Read now
Opass Putcharoen, Tanya Do, Anchalee Avihingsanon & Kiat Ruxrungtham. (2015) Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS. Drug Design, Development and Therapy 9, pages 5763-5769.
Read now
Amedeo Capetti, Maria Vittoria Cossu & Giuliano Rizzardini. (2015) Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance. Expert Opinion on Pharmacotherapy 16:17, pages 2689-2702.
Read now

Articles from other publishers (6)

Alice Tseng, Christine A. Hughes, Janet Wu, Jason Seet & Elizabeth J. Phillips. (2017) Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences. Annals of Pharmacotherapy 51:11, pages 1008-1022.
Crossref
P Echeverría, A Bonjoch, J Puig, A Ornella, B Clotet & E Negredo. (2017) Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV‐1‐infected subjects with dyslipidaemia. HIV Medicine 18:10, pages 782-786.
Crossref
Arun K. Ghosh, Heather L. Osswald & Gary Prato. (2016) Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. Journal of Medicinal Chemistry 59:11, pages 5172-5208.
Crossref
María Jesús Hernández Arroyo, Salvador Enrique Cabrera Figueroa, María Paz Valverde Merino & Alfonso Domínguez-Gil Hurlé. (2016) A pharmacist’s role in the individualization of treatment of HIV patients. Personalized Medicine 13:2, pages 169-188.
Crossref
Elizabeth M. Sherman, Marylee V. Worley, Nathan R. Unger, Timothy P. Gauthier & Jason J. Schafer. (2015) Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection. Clinical Therapeutics 37:9, pages 1876-1893.
Crossref
Sreekumar Othumpangat, John D. Noti & Sidhartha D Ray. 2015. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions 329 348 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.